Daily Stock Reporter is issuing a report on four stocks to watch. Skyline Medical Inc (NASDAQ:SKLN), StemCells Inc (NASDAQ:STEM), Cytori Therapeutics Inc (NASDAQ:CYTX), and Terra Tech Corp (OTCMKTS:TRTC) have been added to our watch list today. Continue reading to find out why. – To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
Skyline Medical Inc (NASDAQ:SKLN) has the patented and FDA approved cleared surgical fluid disposal device, the STREAMWAY System, which eliminates operating room exposure to harmful or off-putting fluids found in the operating room. Dan Felix, Imaging Services Director at Tuscon Medical Center, spoke about his recent STREAMWAY System purchase, “We chose the STREAMWAY System because it’s self-contained, extremely easy to use and, for us, had a return on investment of approximately nine months, with ongoing annual savings of $22,140 a year. That made it one of the easiest purchase requests I’ve ever had to make.” Skyline Medical’s stock has increased 70.59% since the beginning of April. On March 31st, the share price fell as low as $0.17, yet on April 18th, the price rose as high as $0.29.
Stay Informed and Up To Date On The Hottest Small Cap Nasdaq & OTC Plays. Get Them Here.
StemCells Inc (NASDAQ:STEM) is in the business of meeting its clients unmet medical needs through the development and distribution of treatments that are cell-based, on the forefront of medical science, and raise the quality of life for the patient. StemCells’ HuCNS-SC, human neural stem cells for the treatment of chronic cervical spinal cord injury, is currently in clinical phase II, and the interim data regarding its performance has been positive. StemCells, Inc. has seen its share price increase 21.17% in the past trading week, as the positive data pertaining to its treatment was released on April 18th. On April 11th, the stock reached its daily low point of $0.23, but on the day of the data being published, the 18th, the price reached as high as $0.28
Enjoy picks like this? Get These Alerts and More on top small cap Companies before They Rally, Text the phrase “StockAlerts” to 635-66
Cytori Therapeutics Inc (NASDAQ:CYTX) is devoted to harnessing the regenerative nature of stem cells through the distribution of technologies that enable further research into the stem cells potential. Due to the wide number of medical application for stem and regenerative cells, Cytori’s product development pipeline spans across a multitude of illnesses and diseases including cardiovascular disease, renal failure, and pelvic health. The price of Cytori’s stock has increased at a rate of 102.87% over the previous four trading weeks. After experiencing a daily low of $0.16 on March 18th, the price for a share of Cytori rose as high as $0.32 on April 18th.
Stay Informed and Up To Date On The Hottest Small Cap Stocks; Free To Join Now
Terra Tech Corp (OTCMKTS:TRTC) has seen the price of its stock more than double since the beginning of April. On March 31st, the share price fell as low as $0.22, yet on April 18th it rose as high as $0.4749, which is an increase of 119.66%. Terra Tech Corp. is a vertically integrated cannabis-focused agriculture company that is dedicated to creating sustainable solutions for medical cannabis production, extraction and distribution. Additionally, through the use of its exclusive moving table hydroponic system, Terra Tech Corp is able to yield a 30% greater annual harvest, save up to 50% in operating costs, and increase its gross margin by up to 50%.
Small Cap Stock Alerts: Get Them straight to your Cell Phone. To Receive Our Winning Small Cap Stock Alerts For Free, text “StockAlerts” to 63566.
www.DailyStockReporter.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals www.DailyStockReporter.com is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. You can subscribe to the www.DailyStockReporter.com newsletter and start receiving daily alerts. To subscribe by phone and receive messages directly to a mobile phone, text the phrase “StockAlerts” to 63566.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements.
EGM FIRM INC which owns www.DailyStockReporter.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release.
EGM FIRM INC, which owns www.DailyStockReporter.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice.
EGM FIRM INC which owns www.DailyStockReporter.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.
Contact Email: firstname.lastname@example.org
Eanings Review: Rambus Inc. (NASDAQ:RMBS), Revlon Inc (NYSE:REV)
Revlon Inc(NYSE:REV) +2.5% after-hours after announcing that President and CEO Fabian Garcia is stepping down “to pursue other opportunities,” and Executive Vice Chair Paul Meister will oversee operations on an interim basis.
REV also says it expects Q4 revenues of $785M, below $801M from the year-earlier quarter but ahead of analyst consensus estimate of $743M, and a $60M-$80M net loss for the quarter due to a charge related to the recent tax law changes.
REV expects Q4 adjusted EBITDA of $110M-$115M vs. $115M analyst consensus.
CFO Chris Peterson also denies rumors that the company is considering a material asset transfer that would shield assets from lenders.
Rambus Inc.(NASDAQ:RMBS) shares are down 5.5% aftermarket following Q4 results that beat revenue estimates and met on EPS. In-line Q1 guidance (under ASC 605 accounting change) has revenue from $94M to $100M (consensus: $100.38M) and EPS from $0.17 to $0.23 (consensus: $0.18).
Revenue breakdown: Royalties, $77.9M (+10% Y/Y); Product, $8.5M (-27%); Contract and other revenue, $15.5M (+2%); Licensing billings, $76.6M (+18%).Key metrics: Non-GAAP operating margin, 31%; total operating expenses, $67.5M; cash and equivalents, $172.2M; cash flow from operations, $33.3M.
ADTRAN, Inc. (NASDAQ:ADTN) Hits New Lows After Issuing disappointing Earnings Forecast
ADTRAN, Inc.(NASDAQ:ADTN) slumped to a 52-week low after forecasting below consensus guidance for Q4, revising its revenue estimate downward to $125M from $155M-$165M earlier and seeing EPS of ~$0.01; analysts had expected EPS of ~$0.14 and revenue of $161.2M.
ADTN also projects Q1 to come in at roughly the same as Q4, misses analyst consensus of $167.5M.
CEO Tom Stanton says Q4 results have been hurt by a merger-related review, which ADTN expects to be completed in 60-90 days, and slowdown in the spending at a domestic Tier 1 customer.
MKM Partners analyst Michael Genovese believes the customer is CenturyLink (CTL -2%), which accounted for 24% of ADTN’s total sales in 2016.
The analyst thinks the weakness should prove temporary, adding that ADTN’s performance likely will accelerate into 2019 as the company stands to benefit from 5G spending; MKM trims its ADTN target price to $25 from $27 but keeps its Buy rating.
Big IPO Coming: Celator Pharmaceuticals Inc(NASDAQ:CPXX), Moleculin Biotech’s (MBRX)
Today at 10am Eastern, Moleculin Biotech ticker symbol MBRX will debut on the Nasdaq stock exchange and is being considered as one of the most highly anticipated IPO’s of 2016 by the street. The excitement and anticipation is arising from many experts saying that Moleculin Biotech’s (MBRX) drug annamycin is far superior to Celator Pharmaceuticals Inc(NASDAQ:CPXX) drug daunorubicin.
CPXX which has been bought out by Jazz Pharmaceuticals plc – Ordinary Shares(NASDAQ:JAZZ) for $1.5 Billion Dollars last week, share price ran from $1.6 to $31 in 2 months. Moleculin Biotech’s share structure is a 1.5m public float Priced at $6.